|
US5965132A
(en)
|
1992-03-05 |
1999-10-12 |
Board Of Regents, The University Of Texas System |
Methods and compositions for targeting the vasculature of solid tumors
|
|
US6749853B1
(en)
|
1992-03-05 |
2004-06-15 |
Board Of Regents, The University Of Texas System |
Combined methods and compositions for coagulation and tumor treatment
|
|
US7105159B1
(en)
|
1992-11-05 |
2006-09-12 |
Sloan-Kettering Institute For Cancer Research |
Antibodies to prostate-specific membrane antigen
|
|
US6953668B1
(en)
|
1992-11-05 |
2005-10-11 |
Sloan-Kettering Institute For Cancer Research |
Prostate-specific membrane antigen
|
|
US7070782B1
(en)
*
|
1992-11-05 |
2006-07-04 |
Sloan-Kettering Institute For Cancer Research |
Prostate-specific membrane antigen
|
|
US6569432B1
(en)
*
|
1995-02-24 |
2003-05-27 |
Sloan-Kettering Institute For Cancer Research |
Prostate-specific membrane antigen and uses thereof
|
|
US7037647B1
(en)
|
1995-02-24 |
2006-05-02 |
Sloan-Kettering Institute For Cancer Research |
Prostate-specific membrane antigen and uses thereof
|
|
US20030180290A1
(en)
*
|
1995-06-07 |
2003-09-25 |
Idec Pharmaceuticals Corporation |
Anti-CD80 antibody having ADCC activity for ADCC mediated killing of B cell lymphoma cells alone or in combination with other therapies
|
|
US20040253246A1
(en)
*
|
1996-02-23 |
2004-12-16 |
Israeli Ron S. |
Prostate-specific membrane antigen and uses thereof
|
|
US6962981B1
(en)
*
|
1996-03-25 |
2005-11-08 |
Medarex, Inc. |
Monoclonal antibodies specific for the extracellular domain of prostate-specific membrane antigen
|
|
US7381407B1
(en)
|
1996-03-25 |
2008-06-03 |
Medarex, Inc. |
Monoclonal antibodies specific for the extracellular domain of prostate-specific membrane antigen
|
|
US6136311A
(en)
*
|
1996-05-06 |
2000-10-24 |
Cornell Research Foundation, Inc. |
Treatment and diagnosis of cancer
|
|
US6107090A
(en)
|
1996-05-06 |
2000-08-22 |
Cornell Research Foundation, Inc. |
Treatment and diagnosis of prostate cancer with antibodies to extracellur PSMA domains
|
|
EP1710256A1
(en)
*
|
1999-07-29 |
2006-10-11 |
Medarex, Inc. |
Human monoclonal antibodies to prostate specific membrane antigen
|
|
ATE342282T1
(de)
*
|
1999-07-29 |
2006-11-15 |
Medarex Inc |
Humane monoklonale antikörper gegen prostata spezifisches membranantigen
|
|
US6379550B1
(en)
*
|
2000-07-24 |
2002-04-30 |
Health Research, Inc. |
Method for detecting PSA and its molecular forms using thiophilic gel
|
|
US6892140B1
(en)
*
|
2000-11-27 |
2005-05-10 |
Enteron, Inc. |
Immunogenic cancer peptides and uses thereof
|
|
US20020132983A1
(en)
*
|
2000-11-30 |
2002-09-19 |
Junghans Richard P. |
Antibodies as chimeric effector cell receptors against tumor antigens
|
|
JP4463475B2
(ja)
*
|
2001-01-31 |
2010-05-19 |
バイオジェン アイデック インコーポレイテッド |
腫瘍疾患の治療における免疫調節性抗体の使用
|
|
US20030103971A1
(en)
*
|
2001-11-09 |
2003-06-05 |
Kandasamy Hariharan |
Immunoregulatory antibodies and uses thereof
|
|
WO2003008537A2
(en)
*
|
2001-04-06 |
2003-01-30 |
Mannkind Corporation |
Epitope sequences
|
|
WO2002096460A1
(en)
*
|
2001-05-30 |
2002-12-05 |
Cornell Research Foundation, Inc. |
Endopeptidase/anti-psma antibody fusion proteins for treatment of cancer
|
|
US7666414B2
(en)
*
|
2001-06-01 |
2010-02-23 |
Cornell Research Foundation, Inc. |
Methods for treating prostate cancer using modified antibodies to prostate-specific membrane antigen
|
|
US7514078B2
(en)
*
|
2001-06-01 |
2009-04-07 |
Cornell Research Foundation, Inc. |
Methods of treating prostate cancer with anti-prostate specific membrane antigen antibodies
|
|
JP4619651B2
(ja)
*
|
2001-06-01 |
2011-01-26 |
コーネル・リサーチ・ファンデーション・インコーポレイテッド |
前立腺特異的膜抗原に対する修飾抗体およびその使用
|
|
US8507445B2
(en)
|
2001-09-07 |
2013-08-13 |
Board Of Regents, The University Of Texas System |
Compositions and methods of use of targeting peptides for diagnosis and therapy of human cancer
|
|
US7671010B2
(en)
|
2002-08-30 |
2010-03-02 |
The Board Of Regents Of The University Of Texas System |
Compositions and methods of use of targeting peptides for diagnosis and therapy of human cancer
|
|
AU2002305767B2
(en)
*
|
2001-09-20 |
2008-04-10 |
Cornell Research Foundation, Inc. |
Methods and compositions for treating and preventing skin disorders using binding agents specific for PSMA
|
|
WO2003028840A2
(en)
*
|
2001-09-27 |
2003-04-10 |
Board Of Regents, The University Of Texas System |
Combined compositions and methods for tumor vasculature coagulation and treatment
|
|
US20050215472A1
(en)
|
2001-10-23 |
2005-09-29 |
Psma Development Company, Llc |
PSMA formulations and uses thereof
|
|
ES2606537T3
(es)
|
2001-10-23 |
2017-03-24 |
Psma Development Company L.L.C. |
Anticuerpos contra PSMA
|
|
US7399743B2
(en)
*
|
2001-10-26 |
2008-07-15 |
The Scripps Research Institute |
Targeted thrombosis
|
|
US20040018519A1
(en)
*
|
2001-11-16 |
2004-01-29 |
Wright ,Jr. George L |
Methods and devices for quantitative detection of prostate specific membrane antigen and other prostatic markers
|
|
US20070031438A1
(en)
*
|
2001-12-10 |
2007-02-08 |
Junghans Richard P |
Antibodies as chimeric effector cell receptors against tumor antigens
|
|
MXPA04011071A
(es)
|
2002-05-08 |
2005-07-14 |
Northwest Biotherapeutics Inc |
Analisis de calidad para celulas que presentan antigenos.
|
|
KR20110025885A
(ko)
|
2002-07-15 |
2011-03-11 |
더 보드 오브 리전츠 오브 더 유니버시티 오브 텍사스 시스템 |
포스파티딜에탄올아민에 결합하는 펩타이드, 및 바이러스 감염을 치료하는데 있어서 이의 용도
|
|
AU2002364501A1
(en)
*
|
2002-08-30 |
2004-03-19 |
Board Of Regents, The University Of Texas System |
Compositions and methods of use of targeting peptides for diagnosis and therapy of human cancer
|
|
US9701754B1
(en)
|
2002-10-23 |
2017-07-11 |
City Of Hope |
Covalent disulfide-linked diabodies and uses thereof
|
|
US20040136998A1
(en)
*
|
2002-10-30 |
2004-07-15 |
Bander Neil H. |
Methods and compositions for treating or preventing insulin-related disorders using binding agents specific for prostate specific membrane antigen
|
|
DE60323677D1
(de)
*
|
2003-01-10 |
2008-10-30 |
Millennium Pharm Inc |
Verfahren zur bestimmung des wiederauftretens von prostata krebs
|
|
EP1587837B1
(en)
*
|
2003-01-28 |
2012-06-13 |
Proscan RX Pharma Inc. |
Epitope sequences for prostate cancer diagnosis and treatment
|
|
WO2005070456A2
(en)
*
|
2004-01-09 |
2005-08-04 |
Millennium Pharmaceuticals, Inc. |
Diagnosing and treating female reproductive tract or chilhood cancer with pmsa antibodies
|
|
WO2005094882A1
(en)
*
|
2004-03-03 |
2005-10-13 |
Millennium Pharmaceuticals, Inc. |
Modified antibodies to prostate-specific membrane antigen and uses thereof
|
|
WO2005100404A1
(en)
*
|
2004-04-19 |
2005-10-27 |
Proscan Rx Pharma |
Prostate cancer diagnosis and treatment
|
|
MX2007008768A
(es)
*
|
2005-01-21 |
2007-10-19 |
Genentech Inc |
Dosificacion fija de anticuerpos her.
|
|
WO2006089231A2
(en)
*
|
2005-02-18 |
2006-08-24 |
Medarex, Inc. |
Monoclonal antibodies against prostate specific membrane antigen (psma) lacking in fucosyl residues
|
|
US20090226367A1
(en)
*
|
2005-03-11 |
2009-09-10 |
Euro-Celtique S.A. |
Compositions comprising an anti-ca125 antibody and a cytotoxic compound and their use for the treatment of cancer
|
|
CN101141955A
(zh)
*
|
2005-04-08 |
2008-03-12 |
内尔维阿诺医学科学有限公司 |
包含被取代的丙烯酰基偏端霉素衍生物以及抑制生长因子或其受体的抗体的抗肿瘤组合
|
|
LT5414B
(lt)
*
|
2005-04-13 |
2007-04-25 |
Biotechnologijos Institutas |
Monokloninių antikūnų gavimo būdas, hibridomos, gautos šiuo būdu ir rekombinantinės chimerinės į virusus panašios dalelės su įterptais kitų baltymų fragmentais kaip imunogenai hibridomų gavimui šiuo būdu
|
|
US7718775B2
(en)
*
|
2005-04-14 |
2010-05-18 |
Scinopharm Taiwan, Ltd. |
Monoclonal antibody with the capability of neutralizing enterovirus type 71 infection
|
|
EP1726650A1
(en)
*
|
2005-05-27 |
2006-11-29 |
Universitätsklinikum Freiburg |
Monoclonal antibodies and single chain antibody fragments against cell-surface prostate specific membrane antigen
|
|
WO2007109321A2
(en)
|
2006-03-20 |
2007-09-27 |
The Regents Of The University Of California |
Engineered anti-prostate stem cell antigen (psca) antibodies for cancer targeting
|
|
BE1017200A3
(nl)
*
|
2006-07-03 |
2008-04-01 |
Tekni Plex Europ Nv |
Filmstructuur met hoge zuurstofbarriere eigenschappen en werkwijze voor het vervaardigen van zulke filmstructuur.
|
|
EP2162152A2
(en)
*
|
2007-06-01 |
2010-03-17 |
Biogen Idec MA, Inc. |
Cripto binding molecules
|
|
CA2698343C
(en)
|
2007-09-04 |
2018-06-12 |
The Regents Of The University Of California |
High affinity anti-prostate stem cell antigen (psca) antibodies for cancer targeting and detection
|
|
EP2740490A1
(en)
|
2007-10-03 |
2014-06-11 |
Cornell University |
Treatment of proliferative disorders using antibodies to PSMA
|
|
AU2008310908B2
(en)
|
2007-10-12 |
2014-01-09 |
Seagen Inc. |
Combination therapy with antibody-drug conjugates
|
|
US7678581B2
(en)
*
|
2008-01-28 |
2010-03-16 |
Clarient, Inc. |
Correlating chemical and spatial data within pathology samples
|
|
EP2281004A4
(en)
*
|
2008-04-14 |
2012-02-15 |
Proscan Rx Pharma Inc |
PROSTATE-SPECIFIC MEMBRANANT ANTIBODIES AND ANTIGEN-BINDING FRAGMENTS
|
|
EP2727606A3
(en)
|
2008-09-08 |
2015-09-23 |
Psma Development Company, L.L.C. |
Compounds for killing psma-expressing, taxane-resistant cancer cells
|
|
EP2398504B1
(en)
|
2009-02-17 |
2018-11-28 |
Cornell Research Foundation, Inc. |
Methods and kits for diagnosis of cancer and prediction of therapeutic value
|
|
US8772459B2
(en)
|
2009-12-02 |
2014-07-08 |
Imaginab, Inc. |
J591 minibodies and Cys-diabodies for targeting human prostate specific membrane antigen (PSMA) and methods for their use
|
|
TWI582112B
(zh)
|
2011-04-21 |
2017-05-11 |
西雅圖遺傳學公司 |
新穎結合劑－藥物接合物（ＡＤＣｓ）及其用途（二）
|
|
SG194510A1
(en)
|
2011-04-22 |
2013-12-30 |
Emergent Product Dev Seattle |
Prostate-specific membrane antigen binding proteins and related compositionsand methods
|
|
EP2858676B1
(en)
|
2012-06-07 |
2019-03-13 |
Ambrx, Inc. |
Prostate-specific membrane antigen antibody drug conjugates
|
|
WO2013188740A1
(en)
|
2012-06-14 |
2013-12-19 |
Ambrx, Inc. |
Anti-psma antibodies conjugated to nuclear receptor ligand polypeptides
|
|
HUE045435T2
(hu)
|
2012-10-12 |
2019-12-30 |
Medimmune Ltd |
Pirrolobenzodiazepinek és konjugátumaik
|
|
JP6444902B2
(ja)
|
2013-03-13 |
2018-12-26 |
メドイミューン・リミテッドＭｅｄＩｍｍｕｎｅ Ｌｉｍｉｔｅｄ |
ピロロベンゾジアゼピン及びその結合体
|
|
JP6721507B2
(ja)
|
2013-12-23 |
2020-07-15 |
バイエル・ファルマ・アクティエンゲゼルシャフト |
Ｋｓｐ阻害剤との抗体薬物複合体（ａｄｃ）
|
|
JP6531166B2
(ja)
|
2014-09-10 |
2019-06-12 |
メドイミューン・リミテッドＭｅｄＩｍｍｕｎｅ Ｌｉｍｉｔｅｄ |
ピロロベンゾジアゼピン及びそのコンジュゲート
|
|
SG10201908685QA
(en)
|
2015-06-22 |
2019-10-30 |
Bayer Pharma AG |
Antibody drug conjugates (adcs) and antibody prodrug conjugates (apdcs) with enzymatically cleavable groups
|
|
JOP20160154B1
(ar)
*
|
2015-07-31 |
2021-08-17 |
Regeneron Pharma |
أجسام ضادة مضاد لل psma، وجزيئات رابطة لمستضد ثنائي النوعية الذي يربط psma و cd3، واستخداماتها
|
|
ES3020458T3
(en)
|
2015-08-07 |
2025-05-22 |
Imaginab Inc |
Antigen binding constructs to target molecules
|
|
WO2017053469A2
(en)
|
2015-09-21 |
2017-03-30 |
Aptevo Research And Development Llc |
Cd3 binding polypeptides
|
|
WO2017060322A2
(en)
|
2015-10-10 |
2017-04-13 |
Bayer Pharma Aktiengesellschaft |
Ptefb-inhibitor-adc
|
|
CN105524169A
(zh)
*
|
2016-02-03 |
2016-04-27 |
南昌大学 |
一种能特异结合前列腺特异性膜抗原的单域重链抗体
|
|
CN105524170A
(zh)
*
|
2016-02-03 |
2016-04-27 |
南昌大学 |
能特异结合前列腺特异性膜抗原的纳米抗体
|
|
CN105542007A
(zh)
*
|
2016-02-03 |
2016-05-04 |
南昌大学 |
一种能特异结合前列腺特异性膜抗原胞外区的单域重链抗体
|
|
AU2017236431A1
(en)
|
2016-03-24 |
2018-09-27 |
Bayer Pharma Aktiengesellschaft |
Prodrugs of cytotoxic active agents having enzymatically cleavable groups
|
|
CA3027445A1
(en)
|
2016-06-15 |
2017-12-21 |
Bayer Pharma Aktiengesellschaft |
Specific antibody-drug-conjugates (adcs) with ksp inhibitors and anti-cd123-antibodies
|
|
JP2019534882A
(ja)
|
2016-10-11 |
2019-12-05 |
メドイミューン・リミテッドＭｅｄＩｍｍｕｎｅ Ｌｉｍｉｔｅｄ |
免疫介在性療法薬を有する抗体−薬物コンジュゲート
|
|
WO2018114804A1
(de)
|
2016-12-21 |
2018-06-28 |
Bayer Pharma Aktiengesellschaft |
Spezifische antikörper-wirkstoff-konjugate (adcs) mit ksp-inhibitoren
|
|
MX2019007641A
(es)
|
2016-12-21 |
2019-09-09 |
Bayer Pharma AG |
Conjugados de ligando-farmaco (adcs) con grupos escindibles enzimaticamente.
|
|
EP3558386A1
(de)
|
2016-12-21 |
2019-10-30 |
Bayer Aktiengesellschaft |
Prodrugs von cytotoxischen wirkstoffen mit enzymatisch spaltbaren gruppen
|
|
US11266745B2
(en)
|
2017-02-08 |
2022-03-08 |
Imaginab, Inc. |
Extension sequences for diabodies
|
|
JP7062901B2
(ja)
*
|
2017-09-22 |
2022-05-09 |
東ソー株式会社 |
目的細胞の検出方法
|
|
CA3098103A1
(en)
|
2018-05-23 |
2019-11-28 |
Adc Therapeutics Sa |
Molecular adjuvant
|
|
CA3103936A1
(en)
|
2018-06-18 |
2019-12-26 |
Eureka Therapeutics, Inc. |
Constructs targeting prostate-specific membrane antigen (psma) and uses thereof
|
|
WO2022079211A1
(en)
|
2020-10-16 |
2022-04-21 |
Adc Therapeutics Sa |
Glycoconjugates
|
|
GB202102396D0
(en)
|
2021-02-19 |
2021-04-07 |
Adc Therapeutics Sa |
Molecular adjuvant
|
|
CA3236930A1
(en)
|
2021-11-03 |
2022-04-21 |
Hangzhou Dac Biotech Co., Ltd. |
Specific conjugation of an antibody
|
|
TW202442689A
(zh)
|
2023-03-03 |
2024-11-01 |
美商亞森諾生物科學公司 |
靶向ｐｓｍａ及ｃａ９之系統
|